{"id":"W2314401326","doi":"10.5414/cpp44180","title":"Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product","year":2006,"lang":"en","type":"article","venue":"International Journal of Clinical Pharmacology and Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Efavirenz; Bioequivalence; Reverse-transcriptase inhibitor; Pharmacokinetics; Capsule; Bioavailability; Cmax; Pharmacology; Crossover study; Medicine; Chemistry; Human immunodeficiency virus (HIV); Viral load; Virology; Biology; Antiretroviral therapy; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001636274,0.000296208,0.0006937363,0.0002452988,0.0001233576,0.0004777709,0.000263826,0.000479191,0.002510451],"category_scores_gemma":[0.002026482,0.0001949899,0.0004482947,0.0002210361,0.0003345359,0.0004794206,0.0002207863,0.0005049788,0.0002686731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002947044,"about_ca_system_score_gemma":0.0002390159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003320644,"about_ca_topic_score_gemma":0.0001781279,"domain_scores_codex":[0.9989715,0.0004333428,0.00006694825,0.0002228336,0.0002384453,0.00006703016],"domain_scores_gemma":[0.9992066,0.0002468432,0.000285728,0.00007802813,0.00008815477,0.00009461866],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.3314183,0.008391883,0.02231123,0.001099985,0.00106193,0.0004084494,0.0006606609,0.001200308,0.4913283,0.0005868345,0.001007554,0.1405245],"study_design_scores_gemma":[0.021392,0.6958333,0.1495393,0.00009304849,0.001673962,0.001924796,0.000368942,0.005423546,0.1166844,0.0002249628,0.006724485,0.0001174234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979519,0.0008930115,0.0005159657,0.00002819707,0.00002688895,0.00007115205,0.0001368757,0.00001161284,0.0003643657],"genre_scores_gemma":[0.9973962,0.0004102303,0.001133347,0.00005240232,0.0000394138,0.00006992985,0.000404267,0.00000942379,0.0004848845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002510451,"threshold_uncertainty_score":0.008653581,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06567932079286021,"score_gpt":0.4078633520262846,"score_spread":0.3421840312334244,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}